Laxeersiroop (Lactulose)

Lactulose reaches the colon unchanged, where intestinal bacteria break it down into short‑chain fatty acids. This process increases osmotic pressure, drawing water into the bowel to soften stool, and acidifies the colon, converting ammonia to ammonium, which is less readily absorbed, thereby reducing systemic ammonia.

The appropriate dose of Laxeersiroop is determined by a qualified healthcare professional based on the individual’s condition, age, and response to therapy. Prescribers adjust the amount to achieve the desired clinical effect while monitoring for tolerance and side effects.

Safety data for lactulose in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against any possible risks before prescribing Laxeersiroop to pregnant or nursing individuals. Consultation with a specialist is recommended.

To request Laxeersiroop, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Laxeersiroop (lactulose) is an osmotic laxative that works by increasing colonic water content, unlike stimulant laxatives that trigger intestinal muscle contractions. It also has the unique ability to lower ammonia levels, making it useful for hepatic encephalopathy, a benefit not shared by many other laxatives.

Laxeersiroop should be stored at ambient temperature, below 25 °C, in its original container. Protect the product from moisture and direct sunlight to maintain stability and potency throughout its shelf life.

Laxeersiroop is taken orally as a syrup. The dose is measured according to the prescriber’s instructions, usually using a calibrated measuring device. It can be taken with or without food, and the liquid form facilitates easy swallowing, especially for patients who have difficulty with tablets.

Serious risks include severe electrolyte disturbances, dehydration, metabolic acidosis, and rare allergic reactions. Patients should be monitored for signs of these conditions, especially if high doses are used or if they have underlying renal or hepatic impairment.

Laxeersiroop is contraindicated in individuals with known galactosemia and should be used with caution in patients with severe renal or hepatic failure, uncontrolled diabetes, or those prone to severe electrolyte imbalances. A healthcare professional must evaluate suitability before initiating therapy.